Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 8:3:74.
doi: 10.3389/fonc.2013.00074. eCollection 2013.

Ionizing radiation in glioblastoma initiating cells

Affiliations

Ionizing radiation in glioblastoma initiating cells

Maricruz Rivera et al. Front Oncol. .

Abstract

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults with a median survival of 12-15 months with treatment consisting of surgical resection followed by ionizing radiation (IR) and chemotherapy. Even aggressive treatment is often palliative due to near universal recurrence. Therapeutic resistance has been linked to a subpopulation of GBM cells with stem cell-like properties termed GBM initiating cells (GICs). Recent efforts have focused on elucidating resistance mechanisms activated in GICs in response to IR. Among these, GICs preferentially activate the DNA damage response (DDR) to result in a faster rate of double-strand break (DSB) repair induced by IR as compared to the bulk tumor cells. IR also activates NOTCH and the hepatic growth factor (HGF) receptor, c-MET, signaling cascades that play critical roles in promoting proliferation, invasion, and resistance to apoptosis. These pathways are preferentially activated in GICs and represent targets for pharmacologic intervention. While IR provides the benefit of improved survival, it paradoxically promotes selection of more malignant cellular phenotypes of GBM. As reviewed here, finding effective combinations of radiation and molecular inhibitors to target GICs and non-GICs is essential for the development of more effective therapies.

Keywords: DNA damage response; NOTCH; c-MET; glioma initiating cells; radiation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ionizing radiation in combination with c-MET or NOTCH inhibitors prevents tumor recurrence. (A) Treating GBM with IR reduces tumor volume, but radioresistant GICs remain. IR promotes activation of the pro-survival pathways NOTCH and c-MET in GICs, leading to tumor recurrence. (B) Single treatment of GBM tumors with either gamma secretase inhibitors (GSIs) to target NOTCH or tyrosine kinase inhibitors (TKIs) to target c-MET would kill GICs specifically and have a minor effect on tumor volume. (C) Combinatorial treatment of GSIs or TKIs with IR would target both GICs and non-GICs and prevent tumor recurrence.

Similar articles

Cited by

References

    1. Abounader R., Ranganathan S., Lal B., Fielding K., Book A., Dietz H., et al. (1999). Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst. 91, 1548–155610.1093/jnci/91.18.1548 - DOI - PubMed
    1. Amgen. (2012). Analysis of Rilotumumab (AMG 102) Data Identifies a Potential Predictive Biomarker for Patients with Gastric or Gastroesophageal Cancer [Press Release]. Available at: http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1696824
    1. Anido J., Saez-Borderias A., Gonzalez-Junca A., Rodon L., Folch G., Carmona M. A., et al. (2010). TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18, 655–66810.1016/j.ccr.2010.10.023 - DOI - PubMed
    1. Bao S., Wu Q., Li Z., Sathornsumetee S., Wang H., McLendon R. E., et al. (2008). Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 68, 6043–604810.1158/0008-5472.CAN-08-1079 - DOI - PMC - PubMed
    1. Bao S., Wu Q., McLendon R. E., Hao Y., Shi Q., Hjelmeland A. B., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–76010.1038/nature05236 - DOI - PubMed